Company Overview and News

1
Is WisdomTree International Hedged Quality Dividend Growth Fund (IHDG) a Hot ETF Right Now?

2018-10-03 zacks
Making its debut on 05/07/2014, smart beta exchange traded fund WisdomTree International Hedged Quality Dividend Growth Fund (IHDG - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the market.
BATS 4162 EFA DGE DGE DEO IEFA

1
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?

2018-10-01 zacks
The WisdomTree International High Dividend Fund (DTH - Free Report) made its debut on 06/16/2006, and is a smart beta exchange traded fund that provides broad exposure to the Broad Developed World ETFs category of the market.
0941 2454 CHLKF CHL NVS EFA IEFA

5
U.S. Weekly FundFlows Insight Report: Fund Investors Take A Risk-Off Approach For The Week

2018-09-15 seekingalpha - 1
For the second week in three, investors were net redeemers of fund assets (including those of conventional funds and ETFs), withdrawing $3.3 billion net for Lipper's fund-flows week ended September 12, 2018. Fund investors padded the coffers of taxable fixed income funds (+$2.4 billion) but were net redeemers of money market funds (-$3.8 billion), equity funds (-$1.8 billion), and municipal bond funds (-$136 million).
TQQQ FB AAPL MSFT PWV IEFA

 
4 iShares Global Ex-US ETFs: Which One Is Best?

2018-08-23 seekingalpha
As I pointed out in my last article, some people still do not see a difference between ETFs that are similar but not the same. Last time, I wrote a few words about three global ex-U.S. ETFs from Vanguard; in this article, the second in a short series, I will focus on iShares (managed by BlackRock – the world’s biggest asset manager).
IXUS EFA IEFA

4
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?

2018-08-13 zacks
Making its debut on 06/16/2006, smart beta exchange traded fund WisdomTree International High Dividend Fund (DTH - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the market.
BP NVS BP BPAQF EFA BP.A BP.B IEFA

3
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?

2018-07-19 zacks
Launched on 06/16/2006, the WisdomTree International High Dividend Fund (DTH - Free Report) is a smart beta exchange traded fund offering broad exposure to the Broad Developed World ETFs category of the market.
0941 BP CHLKF CHL BP BPAQF EFA BP.A BP.B IEFA

36
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?

2018-06-22 zacks
Making its debut on 06/16/2006, smart beta exchange traded fund WisdomTree International High Dividend Fund (DTH - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
FP BP BP BPAQF EFA BP.A BP.B IEFA

33
What Sectors And Stocks Have ETFs Been Buying?

2018-06-08 seekingalpha
Gold-backed ETF holdings added 72.2 tons to 2,481 tons in April which is the strongest month of net inflows in more than a year.
MAT IVV TRV HAS CINF IVV IEFA

35
Is SPDR MSCI EAFE StrategicFactors ETF (QEFA) a Hot ETF Right Now?

2018-05-28 zacks
The SPDR MSCI EAFE StrategicFactors ETF (QEFA - Free Report) was launched on 06/04/2014, and is a smart beta exchange traded fund designed to offer broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
DUKH AZN DUK EFA IEFA

29
Is WisdomTree International Hedged Quality Dividend Growth Fund (IHDG) a Hot ETF Right Now?

2018-05-16 zacks
Making its debut on 05/07/2014, smart beta exchange traded fund WisdomTree International Hedged Quality Dividend Growth Fund (IHDG - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
HD RHHVF UL UN UNLYF ULVR RHHBY EFA UNLNF IEFA RHHBF

21
ETF Asset Report for April 2018: Bonds Top

2018-04-30 zacks
The month of April was mixed with earnings showing promise and broader markets returning decent returns despite rising yields and trade tensions. Oil has been on an uptrend. Overall, SPDR S&P 500 ETF (SPY - Free Report) gained about 3.5% in a month’s time (as of Apr 27, 2018), SPDR Dow Jones Industrial Average ETF (DIA - Free Report) rose 2.9% while Nasdaq-100-bsed ETF PowerShares QQQ ETF (QQQ - Free Report) jumped 4.
AGG IVV IEMG DIA SPY IVV EFA FLOT SHY IEFA

109
U.S. Weekly FundFlows Insight Report: Fund Flows Remain Positive For The Week In Spite Of Market Declines And Rising Yields

2018-04-27 seekingalpha
For the second week in three, investors were net purchasers of fund assets (including those of conventional funds and ETFs), injecting a little more than $8.0 billion. In spite of market declines and rising yields, fund investors were net purchasers of equity funds (+$3.5 billion), money market funds (+$3.3 billion), taxable bond funds (+$0.9 billion), and municipal bond funds (+$229 million) for the fund flows week ended April 25, 2018.
IVV QQQ CAT IEMG VZ IVV UTX BA IWM IEFA

37
Q1 ETF Inflows Dive at BlackRock: Tough Road Ahead?

2018-04-13 zacks
Unlike preceding quarters,net asset inflows to BlackRock Inc.’s (BLK - Free Report) ETF business dropped 46% in the first quarter to $34.6 billion from the year-ago quarter. However, despite a decline in inflows, BlackRock’s first-quarter 2018 adjusted earnings came in at $6.70 per share, which breezed past the Zacks Consensus Estimate of $6.42.
GD BLK SIG IWD IEMG EFA IEFA EEM SIG

8
Winning ETF Areas of March

2018-04-02 zacks
The month of March was all about the Fed rate hike, trade war fears, the tech market crash and a moderation in Treasury bond yields. Let’s see how investors reacted to this situation and where they parked their money in the month. The data are as of etf.com (as of March 29, 2018) (read: ETF Asset Report for First Quarter of 2017).
VEA O87 IEMG GDX EFA FDN GLD IWM IEFA

8
Wining ETF Areas of March

2018-04-02 zacks
The month of March was all about the Fed rate hike, trade war fears, the tech market crash and a moderation in Treasury bond yields. Let’s see how investors reacted to this situation and where they parked their money in the month. The data are as of etf.com (as of March 29, 2018) (read: ETF Asset Report for First Quarter of 2017).
VEA O87 IEMG GDX EFA FDN GLD IWM IEFA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 46432F842